15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Design Therapeutics Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $21.00 to $21.00, so the covering firms are broadly aligned. The average target of $21.00 sits 77% above the current $11.88. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.36 next quarter toward $-1.64 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Design Therapeutics Inc.
As of Jul, 4 of 4 firms rate DSGN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DSGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.36
Range $-0.38 – $-0.29 · 7 analysts · +20% YoY
Next period, 7 analysts expect Design Therapeutics Inc to earn $-0.36 a share (range $-0.38 – $-0.29), versus $-0.30 a year earlier. Full-year consensus is $-1.36, growing to $-1.64 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Design Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DSGN.
#1
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$20.00+68.4% to target
Overall win rate
34%
+ Follow
#2
KB
Kostas Biliouris
Oppenheimer
Buy
$21.00+76.8% to target
Coverage
—
+ Follow
#3
Faisal Khurshid
Jefferies
Buy
$15.00+26.3% to target
Coverage
—
+ Follow
#4
Joseph Schwartz
Leerink Partners
Buy
$14.00+17.8% to target
Coverage
—
+ Follow
DSGN stock forecast FAQ
What is DSGN's average 12-month price target?+
The 1 analysts with a live target average $21.00 for Design Therapeutics Inc over the next 12 months, ranging from a $21.00 high to a $21.00 low.
Is DSGN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover DSGN?+
4 analysts have an active rating on Design Therapeutics Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering DSGN?+
Among analysts who currently cover DSGN, Yasmeen Rahimi of Piper Sandler has the strongest overall Quantellect track record (Rank #152). Their current call is Buy with a $20.00 target.
What is Design Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.36 per share (range $-0.38 – $-0.29) across 7 analysts. Full-year EPS is projected at $-1.36, rising to $-1.64 the following year.
How much revenue is Design Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading DSGN lately?+
As of Jul, 4 of 4 firms rate DSGN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DSGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
